Aug 26 |
Regeneron gains European approval for bispecific lymphoma drug
|
Aug 26 |
Regeneron’s cancer therapy gets EU approval
|
Aug 26 |
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
Aug 26 |
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
|
Aug 23 |
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
|
Aug 21 |
FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues
|
Aug 21 |
Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
|
Aug 21 |
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
|
Aug 21 |
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
|
Aug 21 |
Regeneron receives anticipated FDA rejection for blood cancer therapy
|